Kidney Fibrosis Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: May 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
7.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Therapeutics, Distribution Channel, And Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global kidney fibrosis treatment market is expected to grow at a revenue CAGR of 7.3% from 2023 to 2031.
Kidney Fibrosis Treatment Market Fundamentals
Kidney fibrosis is a condition in which excess scar tissue accumulates in the kidneys, leading to kidney damage and impaired kidney function. Some common causes of kidney fibrosis include diabetes, hypertension, chronic kidney disease, and various autoimmune diseases. In patients with these conditions, the prevalence of kidney fibrosis can be quite high. For example, in patients with diabetes and chronic kidney disease, the prevalence of kidney fibrosis can be as high as 50%-70%. The kidney fibrosis treatment market includes a variety of treatment options, including pharmaceuticals, biologics, and medical devices. The current standard of care for kidney fibrosis includes angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs), which are used to control blood pressure and reduce proteinuria (excess protein in the urine). Other treatments include antifibrotic drugs, such as pirfenidone and nintedanib, which have been shown to slow the progression of fibrosis. Emerging therapies for kidney fibrosis include novel antifibrotic drugs, such as ASK1 inhibitors, galectin-3 inhibitors, and anti-LOXL2 antibodies, which are currently in clinical trials. Stem cell therapy involves the transplantation of stem cells into the kidney to help repair damaged tissue. This therapy is still in the early stages of research, but it has shown promising results in animal studies. Medical devices, such as extracorporeal shockwave therapy and renal denervation, are also being investigated as potential treatments for kidney fibrosis.
Kidney Fibrosis Treatment Market Dynamics
The global kidney fibrosis treatment market is expected to continue to grow in the coming years as new therapies are developed and the prevalence of kidney fibrosis and chronic kidney disease continues to increase. Kidney fibrosis is becoming increasingly common, with the prevalence of chronic kidney disease on the rise. In the general population, the prevalence of kidney fibrosis is estimated to be around 10%-15%. This has led to an increased demand for kidney fibrosis treatments. Advances in technology have led to the development of new treatments for kidney fibrosis. For example, there are now drugs that can slow or even reverse the progression of kidney fibrosis.
The aging population is more susceptible to kidney fibrosis and related diseases. According to a study published in the American Journal of Kidney Diseases, the prevalence of kidney fibrosis in individuals over the age of 65 was found to be around 38%. Another study published in the Journal of the American Society of Nephrology found that the prevalence of kidney fibrosis increased from 5.5% in individuals aged 45-49 years to 29.8% in those aged 80 years or older. This has created a high kidney fibrosis treatments treatment demand. Healthcare expenditure is increasing globally, and this is expected to continue in the coming years. This is likely to lead to greater investment in the global kidney fibrosis treatment market. Greater awareness about the condition has led to increased diagnosis and treatment of kidney fibrosis. This has created a high demand in the global kidney fibrosis treatment market.
On the other hand, currently, there are limited treatment options available for kidney fibrosis, and most of them focus on managing symptoms rather than treating the underlying cause of the disease. This can be a major kidney fibrosis treatment market challenge. The cost of treatment for kidney fibrosis can be high, especially for patients who require long-term care. This can limit the affordability of treatments for many patients and reduce the demand for treatment options. Kidney fibrosis is a relatively rare disease, and many patients may not be aware of the available treatment options. This can lead to delayed diagnosis and treatment and limit the global kidney fibrosis treatment market growth.
Kidney Fibrosis Treatment Market Ecosystem
The global kidney fibrosis treatment market is analyzed from the following perspectives: therapeutics, distribution channel, and region.
Kidney Fibrosis Treatment Market by Therapeutics
[64564]
Based on the therapeutics, the global kidney fibrosis treatment market is segmented into angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, pirfenidone, renin inhibitors, and vasopeptidase inhibitors.
Angiotensin-converting enzyme (ACE) inhibitors segment accounts for the largest revenue share in the global kidney fibrosis treatment market. ACE inhibitors have been found to be effective in the treatment of kidney fibrosis, a condition in which the kidney tissue becomes scarred and less functional due to chronic inflammation and injury. ACE inhibitors have been shown to slow the progression of kidney fibrosis by reducing the production of angiotensin II, which can cause inflammation and scarring in the kidney tissue. In addition to reducing the production of angiotensin II, ACE inhibitors also increase the levels of bradykinin, a peptide that promotes vasodilation and has anti-inflammatory properties. This can further help to reduce inflammation and fibrosis in the kidneys. These factors support the high proportion of ACE inhibitors in the global kidney fibrosis treatment market share.
Kidney Fibrosis Treatment Market by Distribution Channel
Based on the distribution channels, the global kidney fibrosis treatment market is segmented into hospital pharmacies, retail pharmacies, and others.
The hospital pharmacies segment accounts for a significant share in the global kidney fibrosis treatment market. Drugs used in the treatment of kidney fibrosis may be available in hospital pharmacies and can be dispensed to patients with a prescription from a healthcare provider. Most patients suffering from kidney fibrosis visit hospitals because of the presence of skilled professionals. The sale of drugs in hospital pharmacies is typically governed by strict regulations designed to ensure patient safety and the appropriate use of medications. These regulations may include requirements for the safe storage, handling, and dispensing of medications, as well as guidelines for ensuring that patients receive the correct medication and dosage. Thus, patients are more inclined to buy drugs from this channel.
Kidney Fibrosis Treatment Market by Region
Geographically, the global kidney fibrosis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The market for kidney fibrosis treatments is expected to grow rapidly in North America because of a rise in the number of people suffering from renal illness. However, according to the National Kidney Foundation, chronic kidney disease (CKD) affects approximately 37 million people in the United States and is a major cause of kidney fibrosis. The prevalence of CKD is higher among older adults, African Americans, Hispanics, and individuals with a history of diabetes, high blood pressure, or heart disease. Additionally, throughout the forecast period, the market for kidney fibrosis treatment in North America will benefit from the expanding launch of drugs for end-stage kidney disorders in region like the United States. The growth of the regional market is expected to be driven by the rise in CRO (Contract Research Organization) operations and the sharp increase in healthcare spending in the US and Canada. In 2019, the CDC (Centers for Disease Control and Prevention) predicted that chronic kidney disease would affect roughly 37 million adult people. 15% of the adult population in the US was represented by them. In addition, the CDC notes that polycystic kidney disease and glomerulonephritis affect children over the age of 18 in the United States. The mentioned factors are expected to increase the demand for kidney fibrosis treatment in the US, which will impact regional market dynamics.
The kidney fibrosis treatment market in the Asia Pacific region is expected to experience significant growth during the forecast period. Several factors are driving the kidney fibrosis treatment market growth in the Asia Pacific region. These include the increasing prevalence of kidney diseases, the growing geriatric population, rising healthcare expenditure, and increasing awareness about kidney diseases and their treatments. One study conducted in China, which included 45,868 participants aged 40-75 years, found that the prevalence of kidney fibrosis was 3.3% overall, with a higher prevalence in men than women. Drugs are expected to be the most popular treatment option, accounting for the largest share of the kidney fibrosis treatment market. This is due to the increasing availability of novel drugs and therapies for the treatment of kidney fibrosis. Some of the key players operating in the kidney fibrosis treatment market in the Asia Pacific region include Pfizer, Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Novartis AG, and GlaxoSmithKline plc. These companies are investing heavily in research and development to develop new drugs and therapies for the treatment of kidney fibrosis. Overall, the kidney fibrosis treatment market outlook in the Asia Pacific region is expected to remain promising in the coming years, driven by increasing demand for effective treatments for kidney diseases and rising healthcare expenditure.
The market for kidney fibrosis treatment in Latin America is expected to grow in the coming years due to the increasing prevalence of chronic kidney disease in the region. However, factors such as high drug prices and limited access to healthcare may limit the market growth in this region.
Kidney Fibrosis Treatment Market Competitive Landscape
The global kidney fibrosis treatment market is extremely competitive and consolidated. To survive and succeed in the long run, companies engage in mergers, acquisitions, global expansion, and strategic partnerships. The businesses also intend to put money into sunk costs for ongoing development.
The prominent players operating in the global kidney fibrosis treatment market are: -
Kidney Fibrosis Treatment Market Strategic Developments
Kidney fibrosis, also called renal fibrosis is the final manifestation of chronic kidney disease and is characterized by excess accumulation of extracellular matrix components in the kidneys.
The revenue CAGR for the kidney fibrosis treatment market is 7.3% during the forecast period.
Pfizer Inc., Merck & Co., F. Hoffman-La Roche Ltd., BioLine Rx Ltd., and La Jolla Pharmaceutical Company are some of the major key players in the kidney fibrosis treatment market.
The Asia Pacific region is projected to grow at high revenue CAGR in the global kidney fibrosis treatment market.
Kidney fibrosis is a relatively rare disease, and many patients may not be aware of the available treatment options. This can lead to delayed diagnosis and treatment and limit the growth of the market.
*Insights on financial performance are subject to the availability of information in the public domain